Literature DB >> 25227782

MicroRNAs in colorectal cancer: from diagnosis to targeted therapy.

Ayla Valinezhad Orang1, Abolfazl Barzegari.   

Abstract

Colorectal cancer (CRC) is one of the major healthcare problems worldwide and its processes of genesis include a sequence of molecular pathways from adenoma to carcinoma. The discovery of microRNAs, a subset of regulatory non-coding RNAs, has added new insights into CRC diagnosis and management. Together with several causes of colorectal neoplasia, aberrant expression of oncomiRs (oncogenic and tumor suppressor miRNAs) in cancer cells was found to be indirectly result in up- or down-regulation of targeted mRNAs specific to tumor promoter or inhibitor genes. The study of miRNAs as CRC biomarkers utilizes expression profiling methods from traditional tissue samples along with newly introduced non-invasive samples of faeces and body fluids. In addition, miRNAs could be employed to predict chemo- and radio-therapy responses and be manipulated in order to alleviate CRC characteristics. The scope of this article is to provide a comprehensive review of scientific literature describing aberrantly expressed miRNAs, and consequently dysregulation of targeted mRNAs along with the potential role of miRNAs in CRC diagnosis and prognosis, as well as to summarize the recent findings on miRNA-based manipulation methods with the aim of advancing in anti-CRC therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25227782     DOI: 10.7314/apjcp.2014.15.17.6989

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  30 in total

1.  miR-143 suppresses the proliferation of NSCLC cells by inhibiting the epidermal growth factor receptor.

Authors:  Hong-Bo Zhang; Li-Chao Sun; Lan Ling; Lu-Hong Cong; Rui Lian
Journal:  Exp Ther Med       Date:  2016-07-27       Impact factor: 2.447

Review 2.  miRNAs in gastrointestinal diseases: can we effectively deliver RNA-based therapeutics orally?

Authors:  A K M Nawshad Hossian; Gerardo G Mackenzie; George Mattheolabakis
Journal:  Nanomedicine (Lond)       Date:  2019-11-18       Impact factor: 5.307

3.  miR-503 inhibits cell proliferation and induces apoptosis in colorectal cancer cells by targeting E2F3.

Authors:  Shun-Wu Chang; Jie Yue; Bao-Chun Wang; Xue-Li Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Expression and functional perspectives of miR-184 in pancreatic ductal adenocarcinoma.

Authors:  He Li; Heping Xiang; Weiwei Ge; Hengtong Wang; Tianpeng Wang; Maoming Xiong
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 5.  An update on miRNAs as biological and clinical determinants in colorectal cancer: a bench-to-bedside approach.

Authors:  Wenhao Weng; Junlan Feng; Huanlong Qin; Yanlei Ma; Ajay Goel
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

6.  miR-659-3p is involved in the regulation of the chemotherapy response of colorectal cancer via modulating the expression of SPHK1.

Authors:  Shuyuan Li; Ying Fang; Hai Qin; Wenzheng Fu; Xipeng Zhang
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

7.  Effect of miR-200b on retinal endothelial cell function under high glucose environment.

Authors:  Qun Jiang; Fei Zhao; Xinmin Liu; Rongrong Li; Jianming Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  MiR-15b mediates liver cancer cells proliferation through targeting BCL-2.

Authors:  Yuping Zhang; Feizhou Huang; Jian Wang; Lin Peng; Hongwu Luo
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

9.  Regulator role of HPV E7 protein on miR-21 expression in cervical carcinoma cells and its functional implication.

Authors:  Qingqin Kong; Wenfeng Wang; Ping Li
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

10.  Upregulation of nucleostemin in colorectal cancer and its effects on cell malignancy.

Authors:  Bin Wei; Qiaoying Huang; Xiaogang Zhong
Journal:  Onco Targets Ther       Date:  2015-07-21       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.